Teclistamab
Bispecific Antibodies in Multiple Myeloma: A Combination Leads to Durable Responses
SG Tylor
Bispecific antibodies in multiple myeloma are a new class of drugs that can target two different antigens at the same ...
Clinical Activity Is Provoked by Teclistamab Triplet in R/R Multiple Myeloma
SG Tylor
The Phase Ib (NCT04722146) MajesTEC-2 trial demonstrated promising clinical activity in patients with relapsed/refractory multiple myeloma (RRMM) when combining teclistamab ...
